Immune Checkpoint Blockade

Jarushka Naidoo, David B. Page, Jedd D. Wolchok

Research output: Contribution to journalReview articlepeer-review

Abstract

Since the development and approval of Ipilimumab, the first immune checkpoint inhibitor licensed for the treatment of metastatic melanoma, clinicians have gained a better understanding of the mode of action, management of toxicities, and assessment of response to this class of drugs. Several antibodies are now in development, aimed at blocking novel immune checkpoint molecules, such as PD-1 and it's corresponding ligand PD-L1. This article summarizes the mechanism of action, preclinical development, and subsequent clinical studies of immune checkpoint antibodies in melanoma.

Original languageEnglish (US)
Pages (from-to)585-600
Number of pages16
JournalHematology/Oncology Clinics of North America
Volume28
Issue number3
DOIs
StatePublished - Jun 2014
Externally publishedYes

Keywords

  • Anti-CTLA4
  • Anti-PD-1
  • Anti-PD-L1
  • Checkpoint inhibitor
  • Immunotherapy
  • Ipilimumab
  • Nivolumab
  • Tremelimumab

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Immune Checkpoint Blockade'. Together they form a unique fingerprint.

Cite this